Akebia Therapeutics (AKBA) Receivables (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Receivables data on file, last reported at $62.8 million in Q1 2026.

• On a quarterly basis, Receivables changed 0.42% year-over-year to $62.8 million in Q1 2026; TTM through Mar 2026 was $62.8 million, a 0.42% change from a year earlier, with the FY2025 full-year figure at $49.4 million, up 35.86% from the prior year.
• Receivables for Q1 2026 stood at $62.8 million, up from $49.4 million in the prior quarter.
• Over the last five years, Receivables for AKBA reached as high as $138.6 million in Q2 2022 and fell as low as $18.7 million in Q1 2023.
• Historically, Receivables has averaged $49.9 million across 5 years, with a median of $41.1 million in 2022.
• Across the five-year window, Receivables soared 719.82% in 2022 and tumbled 85.5% in 2023, its largest moves.
• Year by year, Receivables stood at $41.1 million in 2022, then increased by 3.79% to $42.6 million in 2023, then decreased by 19.37% to $34.4 million in 2024, then soared by 43.8% to $49.4 million in 2025, then advanced by 27.14% to $62.8 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $62.8 million in Q1 2026, $49.4 million in Q4 2025, and $66.7 million in Q3 2025.